Dr. Stuart Quin

Dr Stuart Quin appointed as CEO of Medica Group

Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.

Stuart will join Medica from Synlab, a laboratory diagnostic services provider, where he is currently Head of Central and Eastern Europe, Middle East and Africa. Previously he was Synlab’s Group Chief Commercial Officer and Chief Executive of its UK operations. During Stuart’s tenure in the UK he expanded the business by winning new diagnostic service contracts and through the acquisition of four companies that significantly diversified Synlab’s service offering for customers. Prior to joining Synlab, Stuart worked in private equity both as an Investment Director at August Equity and for seven years at 3i in the UK and Germany as an Associate Director focusing on investing in healthcare. Stuart also spent four years at Accenture in the US and UK as a Manager in the health and life sciences strategy consulting practice. Stuart holds a BSc (Hons) in immunology from the University of Edinburgh, a PhD in immunology from Imperial College London and an MBA from INSEAD.

Commenting on his appointment, Stuart Quin said: “I am honoured to have the opportunity to lead Medica through the next phase of its development. The company has a strong reputation of delivering teleradiology services to NHS trusts across the UK. I am looking forward to working with the team at Medica, to identify and execute new growth opportunities and continuing to offer the highest quality service for customers.”